Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis

Inclusion Criteria:

• Aged 18 to 75 years at the screening period.

• Patients who met the diagnostic criteria of allergic rhinitis in Chinese Guidelinesfor the Diagnosis and Treatment of Allergic Rhinitis (revised edition, 2022)

• Positive of at least 1 allergen skin prick test(SPT) and/or serum-specific IgEwithin 1 year before enrollment.

• Subjects have sufficient pollen exposure during the pollen season:

• Subjects' medical history suggested that SAR symptoms were poorly controlled orsubjects' subjective symptoms were not satisfactorily controlled after drugtreatment during the same pollen season in the past.

• On the day of screening, the iTNSS score in the morning was ≥4; At baseline visit,the morning iTNSS was ≥4 points, and the average score of the past 6 rTNSS was ≥6points;

• At baseline visit, the absolute value of peripheral blood eosinophils was ≥0.15×109/L;

• During the screening/induction period, the subjects had good compliance;

• Subjects with asthma who were assessed by the investigator or specialist as havingstable asthma;

• Voluntary participation in this trial and signing the informed consent form

• Subjects (including partners) have no pregnancy and voluntarily take one or morenon-pharmaceutical measures for contraception at period from drug administration to 6 months after the last study drug administration

Exclusion Criteria:

• Laboratory test values did not meet the requirements during screening orrandomization

• Any disease that the investigator believes interferes with the patient's ability tocomplete the entire course of the study;

• Patients with active autoimmune disease

• People with known or suspected immunosuppression

• Subjects with active malignancy or a history of malignancy;

• Active hepatitis or hepatitis B was present during the screening period; Or humanimmunodeficiency virus antibody (Anti-HIV) positive, or treponema pallidum antibody (Anti-TP) positive;

• Diagnosis of helminthic infection within 6 months prior to screening, not receivingstandard treatment or not responding to standard treatment;

• Subjects who have undergone nasal surgery or sinus surgery within 6 months beforescreening

• Subjects have concomitant medical conditions that preclude them from completing thescreening period assessment or evaluating the primary efficacy endpoint;

• Subjects with nasal malignancies and benign tumors;

• History of hypersensitivity to any content of the study drugs or its excipients

• Subjects with a history of systemic allergy to any biological agent;

• Pregnant or lactating women;

• Alcohol, drug and known drug dependence;

• Have a history of vital organ transplantation or hematopoietic stem cell/bone marrowtransplantation;

• Any medical or psychiatric condition that, in the investigator's judgment, puts thesubject at risk, interferes with participation in the study, or interferes with theinterpretation of the study results;

• Any condition that the investigator or primary physician believes may not beappropriate for participating the study